2019 - 2020
Bill and Melinda Gates Foundation
Development of European Region Immunisation Agenda 2030
MMGH supported the Bill & Melinda Gates Foundation in assessing the public health and financial viability of a macrofilaricide drug to accelerate the elimination of onchocerciasis. MMGH coordinated the definition of potential use cases, worked with modellers from the Imperial College London and the Erasmus University Rotterdam to assess its epidemiological and economic impact, assessed the regulatory, product development and drug delivery strategy, and assembled the overall business case.
There are no publications related to: Development of European Region Immunisation Agenda 2030